Life Post-Ranbaxy Laboratories? Sun Pharma Holds On to $300 Million and Hunts for More M&As

MUMBAI: Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Wednesday its $3.2 billion acquisition of smaller rival Ranbaxy Laboratories LtdBSE 1.63 % will not restrict it from making further large acquisitions.

The company will look to invest more than $300 million in research and development and is not considering any job cuts post the close of the deal, Managing Director Dilip Shanghvi told reporters in Mumbai.

Help employers find you! Check out all the jobs and post your resume.

Back to news